Macsita 50 Tablet contains Sitagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Sitagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the body's incretin system. This mechanism increases insulin release from pancreatic beta cells and decreases glucagon secretion from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Macsita 50 is indicated as monotherapy or as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and it may be used in combination with other antidiabetic agents such as metformin or sulfonylureas. The usual dosage is one tablet taken orally once daily, with or without food. Sitagliptin is generally well tolerated; however, patients should be monitored for potential adverse effects including hypersensitivity reactions, pancreatitis, and signs of renal impairment. Dose adjustments may be necessary in patients with moderate to severe renal dysfunction. Macsita 50 should be used as part of a comprehensive diabetes management plan including lifestyle modifications to achieve optimal therapeutic outcomes.